Published in

Elsevier, Annals of Oncology, 6(26), p. 1194-1200, 2015

DOI: 10.1093/annonc/mdv133

Links

Tools

Export citation

Search in Google Scholar

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Journal article published in 2015 by G. Deplanque, M. Demarchi, M. Hebbar, P. Flynn, B. Melichar, J. Atkins, E. Nowara, L. Moyé, D. Piquemal, D. Ritter, P. Dubreuil, C. D. Mansfield, Y. Acin, A. Moussy, O. Hermine ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Two subgroups showing significantly poor survival when treated with single-agent gemcitabine have been identified; one is defined by an overexpression of ACOX1 in blood, and the other via a pain intensity threshold. Masitinib in combination with gemcitabine appears to have a positive benefit–risk ratio in both subgroups. These findings could influence future trial design in pancreatic cancer.